New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

Symptoms, lesion locations, and morphology are among the features clinicians may use to distinguish hand eczema from hand psoriasis in patients.

By Dennis Thompson HealthDay ReporterTHURSDAY, May 29, 2025 (HealthDay News) — Belly flab appears to be a stronger warning ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than ...

A new King’s College London study links abdominal fat—not general obesity—to increased psoriasis risk, especially in women, ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Scalp psoriasis can run the gamut from mild — with thin scales or plaques that are hardly discernible — to severe, with plaques and scales that cover the scalp, forehead, back of the neck ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

Psoriasis is a chronic, inflammatory skin condition, of which there are several types. Knowing what type of psoriasis you have can help you and your doctor come up with an effective treatment plan.